None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis

Wen-Juei Jeng1,4, Chun-Yen Lin1,2, Ji-Yih Chen2,3, Chang-Wen Huang1, Chien-Hao Huang1, I-Shyan Sheen1,2*

1 Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan, 3 Department of Rheumatology, Allergy and Immunology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

Abstract

Background & Aims: A combination of pegylated interferon-alpha and ribavirin (PR) is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B) on sustained virological response (SVR) to PR has been well documented in patients with CHC genotype-1 (GT1), but it is controversial in genotype-2 (GT2) CHC patients. This study investigated the predictability of six single nucleotide polymorphisms (SNP) of IL28B on the treatment responses of PR in patients with CHC GT2.

Method: 197 CHC GT2 consecutive patients who received PR treatment in our prospective cohort were enrolled. Hepatitis C virus (HCV) genotyping, quantification of HCV-RNA and genotyping of the ten SNPs of IL28B were performed. Six SNPs of IL28B were chosen for analysis. The propensity score matching (PSM) analysis was applied using patients with CHC GT1 in another prospective cohort as a positive comparison to avoid covariate bias.

Results: The distribution of the six SNPs was similar in GT1 and GT2 patients. Five of these SNPs had strong association with treatment responses in GT1 but not in GT2 patients. After PSM analysis, these five SNPs still showed strong association with rapid virological response (RVR), cEVR and SVR in GT1 and had no influence in GT2 patients. Furthermore, rs12979860 and baseline viral load were the predictors for both RVR and SVR in GT1 patients. However, only baseline viral load could predict RVR and SVR in GT2 patients. In addition, in patients without RVR, rs12979860 was the only predictor for SVR in GT1 but no predictor for SVR was found in GT2 patients.

Conclusions: The genetic polymorphisms of IL28B had no impact on treatment responses in GT2 patients.

Citation: Jeng W-J, Lin C-Y, Chen J-Y, Huang C-W, Huang C-H, et al. (2012) None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis. PLoS ONE 7(11): e48217. doi:10.1371/journal.pone.0048217

Editor: Golo Ahlenstiel, University of Sydney, Australia

Received January 26, 2012; Accepted September 25, 2012; Published November 16, 2012

Copyright: © 2012 Jeng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NMPR: 98-3112-B-182A-003 and NMPR: 360021 from the National Science Council, Taiwan, and CMRPG 390682, 37542, 360463 from Chang Gung Memorial Hospital. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: issheen.jks@gmail.com

Introduction

Chronic hepatitis C (CHC) is a worldwide health issue affecting around 180 million people. The persistent inflammation caused by this virus may result in cirrhosis and hepatocellular carcinoma. A combination therapy of pegylated interferon-α (PegIFN) and ribavirin (PR) is a standard of care for chronic hepatitis C virus infection [1]. Current treatment strategy for CHC is to tailor the treatment guided by genotypes and on treatment viral response according to the roadmap concept [1,2]. With these recommended strategies, a sustained virological response (SVR) rate could reach around 76–84% among patients with HCV genotype 2/3 (GT2/3) chronic infection, significantly better than the 42–52% in patients with HCV genotype 1 (GT1) [2].

Host genetic factors on the treatment efficacy for CHC have been proposed for a long time due to the ethnic differences in the treatment outcome. Better SVR rates, with 61–80% for GT1 and 80–95% for GT2/3 in Asian patients, were the main supporting evidence [3–12]. Recent genome-wide associated studies demonstrated strong evidence that single nucleotide polymorphisms (SNPs) of Interleukin-28B (IL28B) correlated significantly with SVR in GT1 patients when treated with PR [13–17]. Notably, the frequency of advantageous genotype of IL28B is highest in Asians and lowest in African-Americans, and it parallels the SVR rate in each population [13]. Furthermore, these genotypes of IL28B are also correlated with the spontaneous clearance of hepatitis C virus [14] and with viral kinetics during treatment in GT1 patients [17]. However, the results of the influences of these genetic variances on the treatment responses in GT2 patients were conflicting [18–22].

The aim of the present study was to use the propensity score matching (PSM) analysis to extend our understanding of genetic
association in a cohort of patients with HCV GT2 chronic infection.

Materials and Methods

Patients
We conducted a retrospective analysis of our prospective cohort of consecutive adult Taiwanese patients with CHC GT1 and GT2 who visited the HCV team of the Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital. A universal 24-week regimen of PR (pegylated interferon alfa-2a 180 mcg/week or pegylated interferon alfa-2b 1.5 mcg/Kg/week, ribavirin 1000 mg-1200 mg/day) was reimbursed by the Bureau of National Health Insurance of Taiwan between February 2002 and December 2008. A total of 388 patients who provided written informed consent for this study, including genomic analysis, were enrolled. Patients with decompensated liver disease, hepatoma, co-infection with hepatitis B virus or with human immunodeficiency virus, or with apparent autoimmune hepatitis and alcoholic liver disease, were excluded from this cohort. Twenty-six percent of our patients had a history of blood transfusion, tattooing on skin or eyebrows, patterning of eyes, or piercing of earlobes. The remaining patients had no clear infection routes. Further, the distribution of infection routes in the GT1 and GT2 groups was similar.

Table 1. Baseline characteristics of chronic hepatitis C patients with genotype 1 and 2.

| Variable                  | Total (N = 388) | GT 1 (N = 191) | GT 2 (N = 197) | P value |
|---------------------------|-----------------|----------------|----------------|---------|
| Gender, n (%)             |                 |                |                | 0.128   |
| male                      | 235 (60.6)      | 123 (64.4)     | 112 (56.9)     |         |
| female                    | 153 (39.4)      | 68 (35.6)      | 85 (43.1)      |         |
| Viral load, n (%)         |                 |                |                | 0.044   |
| <0.4×10^6 IU/mL           | 205 (52.8)      | 91 (47.6)      | 114 (57.9)     |         |
| ≥0.4×10^6 IU/mL           | 183 (47.2)      | 100 (52.4)     | 83 (42.1)      |         |
| Fibrosis stage, n (%)     |                 |                |                | 0.410   |
| F0-2                      | 201 (51.8)      | 103 (53.9)     | 98 (49.7)      |         |
| F3-4                      | 187 (48.2)      | 88 (46.1)      | 99 (50.3)      |         |
| Age, y                    | 51.2±10.6       | 51.4±11.1      | 51.1±10.0      | 0.838   |
| BMI, Kg/m²                | 24.5±3.3        | 24.5±3.3       | 24.6±3.2       | 0.603   |
| Hematocrit, %             | 5.7±1.1         | 5.6±1.0        | 5.7±1.1        | 0.430   |
| ALB, g/dL                 | 4.5±0.4         | 4.5±0.4        | 4.5±0.5        | 0.894   |
| AST, IU/L                 | 95±54           | 92±52          | 97±57          | 0.407   |
| ALT, IU/L                 | 153±106         | 149±107        | 157±106        | 0.256   |
| GGT, IU/L                 | 47±48           | 43±48          | 51±47          | 0.188   |
| ALP, IU/L                 | 82±44           | 80±25          | 85±57          | 0.668   |
| Bilirubin, mg/dL          | 0.9±0.4         | 0.9±0.3        | 0.9±0.3        | 0.330   |
| RVR, n (%)                | 293 (75.5)      | 133 (69.6)     | 160 (81.2)     | 0.008   |
| cEVR, n (%)               | 316 (81.4)      | 147 (77.0)     | 169 (85.8)     | 0.025   |
| SVR, n (%)                | 311 (80.2)      | 131 (68.6)     | 180 (91.4)     | <0.001  |

Continuous variables were expressed as mean ± standard deviation; BMI: body mass index; HbA1c: glycohemoglobin; ALB: albumin; AST: aspartate transaminase; ALT: alanine transaminase; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; RVR: rapid virologic response; cEVR: complete early virologic response; SVR: sustained virologic response. doi:10.1371/journal.pone.0048217.t001

All patients received pre-treatment liver biopsies that were evaluated by one liver-specialized pathologist using the Metavir scoring system. HCV genotypes were determined by a genotype-specific probe-based assay in the 5′ untranslated region (LiPA; Innogenetics, Ghent, Belgium).

For analysis of the responses to treatment, subjects with SVR were defined as undetectable serum HCV-RNA 24 weeks after cessation of treatment. The subjects with rapid virological response (RVR) were defined as undetectable serum HCV-RNA 4 weeks after starting treatment. Complete early virological response (cEVR) was defined as undetectable serum HCV-RNA at week 12 after treatment.

The HCV antibody was tested by the Architect anti-HCV (Abbott Diagnostics, Irving, TX, USA). The HCV-RNA was quantitated by the VERSANT HCV RNA 3.0 Assay (bDNA) (Bayer Diagnostics, Tarrytown, NY, USA; lower limit of detection at 3200 copies/ml) or COBAS TaqMan HCV Test (TaqMan HCV; Roche Molecular Systems Inc., Branchburg, NJ, USA; lower limit of detection at concentrations of 15 IU/ml). Those with undetectable RNA by bDNA were reassayed by Cobas Amplicor HCV v2.0 kit (Roche Molecular Systems, Pleasanton, CA, USA; lower limit of detection at concentrations of 100 copies/ml).

Genomic DNA Extraction and IL28B Genotyping

Nucleic acid isolation. Anti-coagulated peripheral blood was obtained from patients with CHC GT1. Genomic DNA was isolated from EDTA anti-coagulated peripheral blood using the Pure gene DNA isolation kit (Gentra Systems, Minneapolis, MN) as previously described [23].

Taqman-based assay for the genotyping of SNPs. The oligonucleotide sequence flanking ten IL28B polymorphisms were designed as primer for Taqman allelic discrimination assays. Both allele specific primers were labeled with a fluorescent dye (FAM and VIC) and used in the PCR reaction. Aliquots of the PCR product were genotyping with allele specific probe of SNPs using real time PCR (AB) [24]. IL28B variants rs12979860 C>T, rs8099917 T>G, rs12980725 A>G, rs105790 T>C, rs7248668 G>A, rs1053728 C>G were diagnosed from whole blood samples using validated pyrosequencing™ assays. We used these six SNPs from ten of our previous report [23] because of significant deviations from the Hardy-Weinberg equilibrium in two SNPs and used one as the representative of the haplotype (three SNPs).

Ethics Statements

All patients in this study had provided written informed consent. This study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of Chang Gung Memorial Hospital.

Statistical Analysis

Chi-square test or Fisher’s exact probability test was used to compare the categorical variables where appropriate. Continuous variables were compared using Mann-Whitney U test or Student’s t-test. Univariate and multivariate logistic regression analyses for the significant independent predictors of virological responses were conducted using patients’ demographics, clinical variables and IL28B SNPs. Variables that achieved statistical P value<0.10 on univariate analysis were entered into multivariate logistic regression analysis. The propensity score matching (PSM) analysis [24–26] was applied for bias reduction in the investigation of the association between SNPs and the treatment outcomes in GT1 and GT2 patients. Variables possibly influencing the treatment
Figure 1. The distribution of the ten SNPs of IL28B between GT1 and GT2. The genotypic distributions of the 10 SNPs of IL28B were similar in GT1 and GT2 patients ($p > 0.05$).

doi:10.1371/journal.pone.0048217.g001

Figure 2. The correlation of SNPs with SVR in GT1 and GT2 patients. Six SNPs were chosen for analysis (rs12979860, rs8099917, rs12980275, rs8105790, rs7248668, 10853728). Five (rs12979860, rs8099917, rs12980275, rs8105790, and rs7248668) of these six SNPs revealed significant association with SVR in GT1 patients while none of them revealed any relationship between these SNPs and the SVR in GT2 patients.

doi:10.1371/journal.pone.0048217.g002
outcomes, including gender, baseline HCV-RNA viral load, fibrosis stage, glycohemoglobin (HbA1c) and basal metabolic index (BMI) were used to generate a propensity score ranging from 0 to 1 by logistic regression. Nearest available matching on the estimated propensity score was used to select the GT1 and find the GT2 subject with the closest propensity score. One hundred and forty-five well-matched pairs of GT1 and GT2 patients were obtained. All P values less than 0.05 by the two-tailed test were considered statistically significant. All statistical analyses were performed with the SPSS statistical software for Windows (version 16, SPSS. Inc., Chicago, IL, USA).

Results

None of the SNPs of IL28B were Associated with SVR in GT2 Patients, though they were in GT1 Patients

The demographic characteristics of these patients are shown in Table 1. There were 191 GT1 and 197 GT2 patients. More patients of GT1 had high viral load (HCV-RNA $\geq 0.4 \times 10^6$ IU/ml) than GT2 patients (GT1 vs. GT2:52.4\% vs. 42.1\%, $p = 0.044$). Other demographic data were comparable between these two groups. Similar to previous literature, the rates of RVR, cEVR and SVR were significantly lower in GT1 patients than GT2 patients (Table 1). The genotypic distributions of the six SNPs of IL28B were similar in GT1 and GT2 patients (Figure 1). Five (rs12979860, rs8099917, rs12980275, rs105790, and rs7248668) of these six SNPs revealed significant association with SVR in GT1 patients. These SNPs had no influence on the SVR in GT2 patients (Table 2).

After balancing the covariates in GT1 and GT2 patients to reduce the bias possibility by the PSM (Table 2), all the treatment responses of GT1 were significantly lower than GT2 (SVR: 68.3\% vs. 89.7\%, $p < 0.001$; RVR: 61.4\% vs. 82.1\%, $p < 0.001$; cEVR: 70.3\% vs. 86.9\%, $p = 0.001$). As for the relationship between the SNPs of IL28B and the treatment responses (Figure 3), five out of the six SNPs showed significant association with RVR, cEVR and SVR in GT1 patients, but none of these SNPs had any relationship with treatment responses in GT2 patients.

Table 2. Baseline characteristics of chronic hepatitis C patients with genotype 1 and 2 after PSM.

| Variable          | Total (N = 290) | GT 1 (N = 145) | GT 2 (N = 145) | P value |
|-------------------|-----------------|----------------|----------------|---------|
| Male, n (%)       | 180 (62.1)      | 90 (62.1)      | 90 (62.1)      | 1.000   |
| RNA $\geq 0.4 \times 10^6$ IU/ml, n (%) | 134 (46.2) | 67 (46.2) | 67 (46.2) | 1.000 |
| Fibrosis stage 3–4, n (%) | 118 (40.7) | 59 (40.7) | 59 (40.7) | 1.000 |
| Age, y            | 50.3±10.7       | 50.0±11.4      | 50.7±10.1      | 0.597   |
| BMI, Kg/m²        | 24.4±3.0        | 24.5±3.2       | 24.4±2.9       | 0.678   |
| HbA1c, %          | 5.7±1.2         | 5.7±1.1        | 5.7±1.2        | 0.699   |
| ALB, g/dL         | 4.5±0.4         | 4.5±0.4        | 4.5±0.4        | 0.278   |
| AST, IU/l         | 93±55           | 92±54          | 94±56          | 0.976   |
| ALT, IU/l         | 156±116         | 153±117        | 159±116        | 0.557   |
| GGTT, IU/L        | 46±50           | 44±54          | 47±46          | 0.882   |
| ALP, IU/l         | 79±25           | 78±25          | 79±26          | 0.574   |
| Bilirubin, mg/dL  | 1.0±0.4         | 1.0±0.3        | 0.9±0.5        | 0.164   |
| RVR, n (%)        | 208 (71.7)      | 89 (61.4)      | 119 (82.1)     | <0.001  |
| cEVR, n (%)       | 228 (78.6)      | 102 (70.3)     | 126 (86.9)     | 0.001   |
| SVR, n (%)        | 229 (79.0)      | 99 (68.3)      | 130 (89.7)     | <0.001  |

doi:10.1371/journal.pone.0048217.t002

Different Predictors for RVR, cEVR and SVR in GT1 and GT2 Patients

Because the SNPs of IL28B had different impacts on the treatment responses in GT1 and GT2 patients, we therefore analyzed the possible predictors for treatment responses in these two PSM adjusted patient groups. In the prediction of RVR, rs12979860 and baseline HCV RNA viral load were the independent predictors in GT1 patients, while baseline HCV-RNA viral load was the only predictor in GT2. In the cEVR prediction analysis, only RVR was the predictor in both GT1 and GT2 patients. As for the SVR, rs12979860, age, baseline viral load and RVR were the predictors in GT1 patients, while BMI, gender and baseline viral load were the predictors in GT2 patients (Table 3).

In our previous report [27], we found that in GT1 patients with RVR, only baseline viral load could predict the SVR. As for GT1 patients without RVR, rs12979860 became the predictor for SVR. Similar observation was found in GT1 patients in this PSM analysis. However, in GT2 patients with RVR, baseline RNA, fibrosis and ALT levels were the predictors for SVR. Interestingly, none of these factors including SNPs of IL28B were associated with SVR in GT2 patients without RVR (Table 4).

Discussion

The treatment of CHC has evolved rapidly. Response to tailored treatment planning has been emphasized after a roadmap concept is established [2]. The discovery of the host genome factors of IL-28B was a milestone since it demonstrated and explained the influence of genetic variations and ethnicity on the efficacy of interferon-based therapy for patients with GT1 CHC [28,29]. In our previous report, by genotyping six SNPs of IL28B, we had shown a significant correlation of genetic polymorphisms of IL28B with SVR in GT1 Asian patients [27]. The present study revealed that none of the six SNPs had association with either RVR or SVR in Asian GT2 patients, even by PSM approach.

Though the impact of polymorphisms of IL28B on the treatment responses of GT1 patients is very clear, the impact of this genetic polymorphism on the treatment responses in GT2
patients is still controversial [18–22]. Rauch et al. had reported that genotype of rs8099917 had no significant impact on the SVR in Swiss patients infected with HCV GT2 or 3 [15]. Yu et al. [19] found no influence of rs8099917 on SVR of Asian HCV GT2 patients, but a higher RVR rate in those with TT rs8099917. On the other hand, in Italian patients, Mangia [18], Lindh [20] and Sarrazin [21] reported that the genotype of rs12979860 had significant association with SVR in patients with HCV GT2 or GT3 infection. Kawaoka [22] found that the initial viral load and rs8099917 genotype are significantly independent predictors of SVR in genotype 2 patients in Japan.

The three reports [18,20,21] about the impact of IL28B on the treatment outcomes of chronic hepatitis C GT2 or GT3 patients showed IL28B polymorphism was associated with SVR in the 24-week treatment and the effect was only observed in the non-RVR patients. In one of them, Sarrazin et al. [21] claimed only GT3 but not GT2 patients had a significantly higher SVR rate in the patients with advantageous allele. The other two did not further

Figure 3. The role of SNPs in RVR (3A), EVR (3B) and SVR (3C) between GT1 and GT2 after PSM analysis. Five out of these SNPs (rs12979860, rs8099917, rs12980275, rs8105790, rs7248668) showed significant association with RVR, cEVR and SVR in GT1 patients but none of these SNPs had relationship with treatment responses in GT2 patients.

doi:10.1371/journal.pone.0048217.g003
Table 3. Predictors for RVR, cEVR and SVR in both GT1 and GT2 patients after PSM.

| Variables | UV OR  | P value | MV OR  | 95% CI  | P value |
|-----------|--------|---------|--------|---------|---------|
| RVR GT1   |        |         |        |         |         |
| rs12979860| 10.49  | <0.001  | 13.0   | 3.3–51.0| <0.001  |
| rs8099917 | 5.08   | 0.004   |        |         |         |
| rs12980275| 7.08   | 0.001   |        |         |         |
| rs8105790 | 5.08   | 0.004   |        |         |         |
| rs7248668 | 7.08   | 0.001   |        |         |         |
| rs10853728| 1.92   | 0.069   |        |         |         |
| HbA1c     | 0.81   | 0.161   |        |         |         |
| Viral load| 3.83   | <0.001  | 4.5    | 2.1–9.7 | <0.001  |
| GT2       |        |         |        |         |         |
| HbA1c     | 0.99   | 0.995   |        |         |         |
| Viral load| 2.61   | 0.034   | 2.6    | 1.1–6.3 | 0.034   |
| cEVR GT1  |        |         |        |         |         |
| rs12979860| 8.41   | <0.001  |        |         |         |
| rs8099917 | 4.67   | 0.003   |        |         |         |
| rs12980275| 6.19   | 0.001   |        |         |         |
| rs8105790 | 4.67   | 0.033   |        |         |         |
| rs7248668 | 6.19   | 0.001   |        |         |         |
| rs10853728| 1.90   | 0.088   |        |         |         |
| BMI       | 0.89   | 0.039   |        |         |         |
| GGT       | 0.99   | 0.068   |        |         |         |
| ALP       | 0.99   | 0.058   |        |         |         |
| RVR       | 264.00 | <0.001  | 264.0  | 33.6–2075.0| <0.001 |
| Viral load| 4.05   | <0.001  |        |         |         |
| GT2       |        |         |        |         |         |
| BMI       | 0.82   | 0.032   |        |         |         |
| GGT       | 1.01   | 0.214   |        |         |         |
| ALP       | 0.98   | 0.068   |        |         |         |
| RVR       | 265.50 | <0.001  | 265.5  | 31.3–2250.3| <0.001 |
| Viral load| 1.72   | 0.277   |        |         |         |
| SVR GT1   |        |         |        |         |         |
| rs12979860| 5.47   | 0.002   | 4.4    | 1.2–16.8| 0.028   |
| rs8099917 | 4.13   | 0.007   |        |         |         |
| rs12980275| 4.13   | 0.007   |        |         |         |
| rs8105790 | 4.13   | 0.007   |        |         |         |
| rs7248668 | 4.13   | 0.007   |        |         |         |
| rs10853728| 1.86   | 0.095   |        |         |         |
| Age       | 0.97   | 0.044   | 0.96   | 0.9–0.99| 0.033   |
| BMI       | 0.86   | 0.010   |        |         |         |
| Gender    | 2.09   | 0.043   |        |         |         |
| Viral load| 4.85   | <0.001  | 4.2    | 1.7–10.3| 0.002   |
| Fibrosis stage | 2.28 | 0.024 |        |         |         |
| RVR       | 7.14   | <0.001  | 3.8    | 1.6–9.1 | 0.003   |
| cEVR      | 5.36   | <0.001  |        |         |         |
| GT2       |        |         |        |         |         |
| Age       | 0.99   | 0.822   |        |         |         |
| BMI       | 0.78   | 0.015   | 0.8    | 0.7–1.0 | 0.049   |
divide their patients into GT2 and GT3 groups [18,20]. However, genotype 2 and 3 are not really the same [30,31]. Here, our patients are all GT2 HCV infections, and no associations between treatment outcomes (SVR or RVR) and rs12979860 polymorphism were found. In our study, the polymorphism of IL28B SNPs influences the RVR in GT1 patients rather than GT2 patients.

In addition, the distribution of the homozygous responding allele was around 40% in Caucasians but it is the dominant pattern (about 90%) in our patients. Furthermore, the dosage of pegylated interferon and ribavirin varied among Western studies (PEG-INTRON: 1.0 or 1.5 mcg/kg/week; ribavirin: 600–1400 mg/day), and treatment duration varied from 12 weeks to 24 weeks. In the present study, we used a fixed dosage of PegIFN and RBV (PEG-INTRON: 1.5 mcg/kg/week or pegasys 180 mcg/week; ribavirin: 1000–1200 mg/day), and a fixed duration (24 weeks). These factors may also contribute to the different conclusions in different studies.

To investigate the association between SNPs and treatment outcome in an observational database rather than a randomized control trial, a propensity score matching analysis was an

Table 3. Cont.

| Variables | UV | 95% CI | P value | MV | 95% CI | P value |
|-----------|----|--------|---------|----|--------|---------|
| Gender    | 5.38 | 0.2 | 0.006 | 7.4 | 1.5–35.7 | 0.013 |
| Viral load| 9.15 | 7.4 | 0.005 | 1.5–35.7 | 0.013 |
| Fibrosis stage | 4.70 | 2.60 | 0.110 | 2.79 | 0.112 |
| RVR       | 1.01 | 1.0 | 0.030 | 4.08 | 0.044 |
| eEVR      | 1.01 | 1.0 | 0.044 |

UV: Univariate analysis; MV: Multivariate analysis.
doi:10.1371/journal.pone.0048217.t003

Table 4. Predictors for SVR in both GT1 and GT2 patients with or without RVR after PSM.

| Variables | With RVR | 95% CI | P value | Without RVR | 95% CI | P value |
|-----------|----------|--------|---------|-------------|--------|---------|
| GT-1      | rs12979860 | 4.20 | 0.045 | rs10853728 | 4.08 | 0.044 |
| rs8099917 | 1.37 | 3.18 | 0.111 | rs7248668 | 4.08 | 0.044 |
| rs12980275| 1.55 | 3.67 | 0.071 | rs10853728 | 4.08 | 0.044 |
| rs8105790 | 1.37 | 3.18 | 0.111 | rs12979860 | 4.20 | 0.045 |
| rs7248668 | 1.85 | 2.27 | 0.219 | rs8099917 | 1.37 | 3.18 |
| rs10853728| 1.03 | 2.00 | 0.215 | | | |
| Age       | 0.98 | 0.96 | 0.094 |
| Gender    | 3.83 | 1.56 | 0.431 |
| BMI       | 0.883 | 0.85 | 0.109 |
| Viral Load| 4.63 | 2.54 | 0.107 |
| Fibrosis stage | 2.83 | 1.59 | 0.397 |
| GPT       | 1.01 | 1.00 | 0.939 |
| GTT       | 1.02 | 0.99 | 0.544 |

| Variables | GT-2 | 95% CI | P value |
|-----------|------|--------|---------|
| Age       | 1.01 | 0.95 | 0.350 |
| Gender    | 3.04 | 1.48 | 0.220 |
| BMI       | 0.77 | 0.86 | 0.369 |
| Viral Load| 6.38 | 9.00 | 0.065 |
| Fibrosis stage | 3.58 | 12.80 | 0.038 |
| GPT       | 1.01 | 1.01 | 0.466 |
| GTT       | 1.01 | 1.00 | 0.902 |

doi:10.1371/journal.pone.0048217.t004
important method used to reduce patient selection bias [24–26] and to avoid imbalance covariates between groups. Through PSM, we used GT1 patients as a comparison group to match covariates that had been reported to influence treatment responses between GT1 and GT2 patient groups. The results still demonstrated the SNPs (rs12979860, rs8099917, rs2980275, rs8105790, and rs7248668) had no relationship with SVR in GT2 patients, though two reports from Europe [18,20] showed that the SNP of IL28B had a significant impact on SVR in GT2 or GT3 patients who did not achieve RVR. The majority of their patients were genotype 3 and the response to PR treatment was not as good in genotype 3 as it was in genotype 2. Therefore, further studies on the association of IL28B and SVR in only genotype 2 Caucasian patients are needed.

The limitation of this study is that the sample size was not big enough. Further external validation in larger populations as well as in Western countries is necessary. In addition, hidden bias may remain even after PSM because of matching only the controls for observed variables (to the extent that they are perfectly measured).

In conclusion, our data demonstrated that none of the six SNPs of IL28B had any relationship with SVR in GT2 patients, irrespective of the overall number of patients, or in those with or without RVR.

Acknowledgments

We greatly appreciated the secretarial and clerical help from Hui-Chuan Cheng, Mon-Tzy Lu and Pei-Ling Lin.

Author Contributions

Conceived and designed the experiments: CYL ISS JYC. Performed the experiments: CYL ISS JYC. Analyzed the data: CWH. Contributed reagents/materials/analysis tools: ISS CYL JYC. Wrote the paper: WJJ. Revised the manuscript for important intellectual content: WJJ CHH.

References

1. Davis GL, Allbright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331–338.
2. Ghany MG, Strader DB, Thomas DL, Siffert LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335–1374.
3. Manns MP, McHughon JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 353: 950–957.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
5. Bruno S, Canna C, Di Marco V, Rumi M, Vincenzi C, et al. (2004) Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 41: 474–481.
6. Hadziyannis SJ, Sette H, Jr., Morgan TB, Balan V, Diago M, et al. (2004) Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
7. Mangia A, Santoro R, Mineva N, Ricci GL, Carretta V, et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609–2617.
8. von Wagen M, Huber M, Berg T, Hinrichsen H, Rasenack J, et al. (2005) Peginterferon-alfa2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522–527.
9. Shiffman ML, Sutter F, Bacon BR, Nelson D, Harley H, et al. (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357: 124–134.
10. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, et al. (2007) A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 133: 219–226.
11. Rumi MG, Agnello A, Pratt GM, D’Ambrosio R, Donato MF, et al. (2010) Randomised study of peginterferon-alpha2a plus ribavirin vs peginterferon-alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology 138: 346–355.
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shiffman M, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 599–601.
13. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
28. Alfihal NH, McHutchison JG, Zeuzem S, Mangia A, Pavlotsky JM, et al. (2011) Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53: 336–345.
29. Rauch A, Kutákik Z, Descombes P, Cai T, Di Isidio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338–1345, 1345 e1331–1337.
30. Rizzetto HS, Ackrill AM (2004) Sustained virological response (SVR) to Peginterferon Alfa-2A (40KD) (PEGASYS) plus ribavirin (Copegus): comparison of outcomes in patients infected with HCV genotype 2 and 3. Hepatology 40: 252A.
31. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993–999.
32. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, et al. (2008) Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47: 1884–1893.
33. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, et al. (2004) Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39: 1721–1731.